The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Lysosomal Storage Disease (LSD)-Global Market Insights and Sales Trends 2025
Synopsis
Lysosomal Storage Disease (LSD) is a genetic disorder that causes various types of nervous system disorders such as clinical abnormalities and cellular dysfunction. There are more than 65 categories of LSD. This disease can be classified into Lipid Metabolism Disorder and Glycoprotein Metabolism Disorder. Further Lipid Metabolism Disorder is categorized into Gaucher disease & Fabry disease and Glycoprotein Metabolism Disorder into Pompe disease. LSD develops mainly due to deficiency of lysosomal enzyme in the living body. A person suffering from LSD could experience problems like abnormal growth of bones, delay movement of body, deafness, blindness, dementia, respiratory problems, fatigue/weakness, bone & joint deformity, organ enlargement, lung dysfunction, severe & fatal physical & mental health deterioration.
The global Lysosomal Storage Disease (LSD) market size is expected to reach US$ 10460 million by 2029, growing at a CAGR of 4.9% from 2023 to 2029. The market is mainly driven by the significant applications of Lysosomal Storage Disease (LSD) in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Lysosomal Storage Disease (LSD) market. Lipid Metabolism Disorder, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Glycoprotein Metabolism Disorder segment is estimated at % CAGR for the next seven-year period.
The global LSD market is expected to grow with growing Ashkenazi (Eastern and Western Europe) population, increasing pharmaceutical R&D spending, growing disposable income, rising healthcare expenditure and accelerating economic growth. Key trends of this rare disease market includes progressing drugs under pipeline and increasing preference towards gene therapy. However, there are some factors which can hinder growth of the market including stringent regulations and limited access to patent rights.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Lysosomal Storage Disease (LSD), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Lysosomal Storage Disease (LSD) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Lysosomal Storage Disease (LSD) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Lysosomal Storage Disease (LSD) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Lysosomal Storage Disease (LSD) covered in this report include Actelion Pharmaceuticals, Amicus Therapeutics, Arena Pharmaceuticals, Astellas Pharma, Astrazeneca, Biomarin Pharmaceutical, Eli Lilly, Lexicon Pharmaceuticals and Novo Nordisk, etc.
The global Lysosomal Storage Disease (LSD) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Actelion Pharmaceuticals
Amicus Therapeutics
Arena Pharmaceuticals
Astellas Pharma
Astrazeneca
Biomarin Pharmaceutical
Eli Lilly
Lexicon Pharmaceuticals
Novo Nordisk
Merck
Global Lysosomal Storage Disease (LSD) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Lysosomal Storage Disease (LSD) market, Segment by Type:
Lipid Metabolism Disorder
Glycoprotein Metabolism Disorder
Global Lysosomal Storage Disease (LSD) market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Lysosomal Storage Disease (LSD) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Lysosomal Storage Disease (LSD) is a genetic disorder that causes various types of nervous system disorders such as clinical abnormalities and cellular dysfunction. There are more than 65 categories of LSD. This disease can be classified into Lipid Metabolism Disorder and Glycoprotein Metabolism Disorder. Further Lipid Metabolism Disorder is categorized into Gaucher disease & Fabry disease and Glycoprotein Metabolism Disorder into Pompe disease. LSD develops mainly due to deficiency of lysosomal enzyme in the living body. A person suffering from LSD could experience problems like abnormal growth of bones, delay movement of body, deafness, blindness, dementia, respiratory problems, fatigue/weakness, bone & joint deformity, organ enlargement, lung dysfunction, severe & fatal physical & mental health deterioration.
The global Lysosomal Storage Disease (LSD) market size is expected to reach US$ 10460 million by 2029, growing at a CAGR of 4.9% from 2023 to 2029. The market is mainly driven by the significant applications of Lysosomal Storage Disease (LSD) in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Lysosomal Storage Disease (LSD) market. Lipid Metabolism Disorder, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Glycoprotein Metabolism Disorder segment is estimated at % CAGR for the next seven-year period.
The global LSD market is expected to grow with growing Ashkenazi (Eastern and Western Europe) population, increasing pharmaceutical R&D spending, growing disposable income, rising healthcare expenditure and accelerating economic growth. Key trends of this rare disease market includes progressing drugs under pipeline and increasing preference towards gene therapy. However, there are some factors which can hinder growth of the market including stringent regulations and limited access to patent rights.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Lysosomal Storage Disease (LSD), with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Lysosomal Storage Disease (LSD) market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Lysosomal Storage Disease (LSD) market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Lysosomal Storage Disease (LSD) sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Lysosomal Storage Disease (LSD) covered in this report include Actelion Pharmaceuticals, Amicus Therapeutics, Arena Pharmaceuticals, Astellas Pharma, Astrazeneca, Biomarin Pharmaceutical, Eli Lilly, Lexicon Pharmaceuticals and Novo Nordisk, etc.
The global Lysosomal Storage Disease (LSD) market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Actelion Pharmaceuticals
Amicus Therapeutics
Arena Pharmaceuticals
Astellas Pharma
Astrazeneca
Biomarin Pharmaceutical
Eli Lilly
Lexicon Pharmaceuticals
Novo Nordisk
Merck
Global Lysosomal Storage Disease (LSD) market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Lysosomal Storage Disease (LSD) market, Segment by Type:
Lipid Metabolism Disorder
Glycoprotein Metabolism Disorder
Global Lysosomal Storage Disease (LSD) market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Lysosomal Storage Disease (LSD) companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Lysosomal Storage Disease (LSD)
1.1 Lysosomal Storage Disease (LSD) Market Overview
1.1.1 Lysosomal Storage Disease (LSD) Product Scope
1.1.2 Lysosomal Storage Disease (LSD) Market Status and Outlook
1.2 Global Lysosomal Storage Disease (LSD) Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Lysosomal Storage Disease (LSD) Market Size by Region (2018-2029)
1.4 Global Lysosomal Storage Disease (LSD) Historic Market Size by Region (2018-2023)
1.5 Global Lysosomal Storage Disease (LSD) Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Lysosomal Storage Disease (LSD) Market Size (2018-2029)
1.6.1 North America Lysosomal Storage Disease (LSD) Market Size (2018-2029)
1.6.2 Europe Lysosomal Storage Disease (LSD) Market Size (2018-2029)
1.6.3 Asia-Pacific Lysosomal Storage Disease (LSD) Market Size (2018-2029)
1.6.4 Latin America Lysosomal Storage Disease (LSD) Market Size (2018-2029)
1.6.5 Middle East & Africa Lysosomal Storage Disease (LSD) Market Size (2018-2029)
2 Lysosomal Storage Disease (LSD) Market by Type
2.1 Introduction
2.1.1 Lipid Metabolism Disorder
2.1.2 Glycoprotein Metabolism Disorder
2.2 Global Lysosomal Storage Disease (LSD) Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Lysosomal Storage Disease (LSD) Historic Market Size by Type (2018-2023)
2.2.2 Global Lysosomal Storage Disease (LSD) Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Lysosomal Storage Disease (LSD) Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Lysosomal Storage Disease (LSD) Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Lysosomal Storage Disease (LSD) Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Lysosomal Storage Disease (LSD) Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Lysosomal Storage Disease (LSD) Revenue Breakdown by Type (2018-2029)
3 Lysosomal Storage Disease (LSD) Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
3.2 Global Lysosomal Storage Disease (LSD) Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Lysosomal Storage Disease (LSD) Historic Market Size by Application (2018-2023)
3.2.2 Global Lysosomal Storage Disease (LSD) Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Lysosomal Storage Disease (LSD) Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Lysosomal Storage Disease (LSD) Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Lysosomal Storage Disease (LSD) Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Lysosomal Storage Disease (LSD) Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Lysosomal Storage Disease (LSD) Revenue Breakdown by Application (2018-2029)
4 Lysosomal Storage Disease (LSD) Competition Analysis by Players
4.1 Global Lysosomal Storage Disease (LSD) Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Lysosomal Storage Disease (LSD) as of 2022)
4.3 Date of Key Players Enter into Lysosomal Storage Disease (LSD) Market
4.4 Global Top Players Lysosomal Storage Disease (LSD) Headquarters and Area Served
4.5 Key Players Lysosomal Storage Disease (LSD) Product Solution and Service
4.6 Competitive Status
4.6.1 Lysosomal Storage Disease (LSD) Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Actelion Pharmaceuticals
5.1.1 Actelion Pharmaceuticals Profile
5.1.2 Actelion Pharmaceuticals Main Business
5.1.3 Actelion Pharmaceuticals Lysosomal Storage Disease (LSD) Products, Services and Solutions
5.1.4 Actelion Pharmaceuticals Lysosomal Storage Disease (LSD) Revenue (US$ Million) & (2018-2023)
5.1.5 Actelion Pharmaceuticals Recent Developments
5.2 Amicus Therapeutics
5.2.1 Amicus Therapeutics Profile
5.2.2 Amicus Therapeutics Main Business
5.2.3 Amicus Therapeutics Lysosomal Storage Disease (LSD) Products, Services and Solutions
5.2.4 Amicus Therapeutics Lysosomal Storage Disease (LSD) Revenue (US$ Million) & (2018-2023)
5.2.5 Amicus Therapeutics Recent Developments
5.3 Arena Pharmaceuticals
5.3.1 Arena Pharmaceuticals Profile
5.3.2 Arena Pharmaceuticals Main Business
5.3.3 Arena Pharmaceuticals Lysosomal Storage Disease (LSD) Products, Services and Solutions
5.3.4 Arena Pharmaceuticals Lysosomal Storage Disease (LSD) Revenue (US$ Million) & (2018-2023)
5.3.5 Astellas Pharma Recent Developments
5.4 Astellas Pharma
5.4.1 Astellas Pharma Profile
5.4.2 Astellas Pharma Main Business
5.4.3 Astellas Pharma Lysosomal Storage Disease (LSD) Products, Services and Solutions
5.4.4 Astellas Pharma Lysosomal Storage Disease (LSD) Revenue (US$ Million) & (2018-2023)
5.4.5 Astellas Pharma Recent Developments
5.5 Astrazeneca
5.5.1 Astrazeneca Profile
5.5.2 Astrazeneca Main Business
5.5.3 Astrazeneca Lysosomal Storage Disease (LSD) Products, Services and Solutions
5.5.4 Astrazeneca Lysosomal Storage Disease (LSD) Revenue (US$ Million) & (2018-2023)
5.5.5 Astrazeneca Recent Developments
5.6 Biomarin Pharmaceutical
5.6.1 Biomarin Pharmaceutical Profile
5.6.2 Biomarin Pharmaceutical Main Business
5.6.3 Biomarin Pharmaceutical Lysosomal Storage Disease (LSD) Products, Services and Solutions
5.6.4 Biomarin Pharmaceutical Lysosomal Storage Disease (LSD) Revenue (US$ Million) & (2018-2023)
5.6.5 Biomarin Pharmaceutical Recent Developments
5.7 Eli Lilly
5.7.1 Eli Lilly Profile
5.7.2 Eli Lilly Main Business
5.7.3 Eli Lilly Lysosomal Storage Disease (LSD) Products, Services and Solutions
5.7.4 Eli Lilly Lysosomal Storage Disease (LSD) Revenue (US$ Million) & (2018-2023)
5.7.5 Eli Lilly Recent Developments
5.8 Lexicon Pharmaceuticals
5.8.1 Lexicon Pharmaceuticals Profile
5.8.2 Lexicon Pharmaceuticals Main Business
5.8.3 Lexicon Pharmaceuticals Lysosomal Storage Disease (LSD) Products, Services and Solutions
5.8.4 Lexicon Pharmaceuticals Lysosomal Storage Disease (LSD) Revenue (US$ Million) & (2018-2023)
5.8.5 Lexicon Pharmaceuticals Recent Developments
5.9 Novo Nordisk
5.9.1 Novo Nordisk Profile
5.9.2 Novo Nordisk Main Business
5.9.3 Novo Nordisk Lysosomal Storage Disease (LSD) Products, Services and Solutions
5.9.4 Novo Nordisk Lysosomal Storage Disease (LSD) Revenue (US$ Million) & (2018-2023)
5.9.5 Novo Nordisk Recent Developments
5.10 Merck
5.10.1 Merck Profile
5.10.2 Merck Main Business
5.10.3 Merck Lysosomal Storage Disease (LSD) Products, Services and Solutions
5.10.4 Merck Lysosomal Storage Disease (LSD) Revenue (US$ Million) & (2018-2023)
5.10.5 Merck Recent Developments
6 North America
6.1 North America Lysosomal Storage Disease (LSD) Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Lysosomal Storage Disease (LSD) Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Lysosomal Storage Disease (LSD) Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Lysosomal Storage Disease (LSD) Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Lysosomal Storage Disease (LSD) Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Lysosomal Storage Disease (LSD) Market Dynamics
11.1 Lysosomal Storage Disease (LSD) Industry Trends
11.2 Lysosomal Storage Disease (LSD) Market Drivers
11.3 Lysosomal Storage Disease (LSD) Market Challenges
11.4 Lysosomal Storage Disease (LSD) Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
